Israel Biotech Fund participated in Gamida Cell’s $40MM financing round which shall support the ongoing Phase 3 trial of the its FDA Breakthrough Designated clinical-stage product, NiCord, to facilitate bone marrow transplantation. Read the full Article
Gamida Cell $40MM Financing to support its Phase 3 Trial
![](http://ibf.fund/wp-content/uploads/2019/01/Screen-Shot-2017-06-19-at-15.15.55-1-e1497879619569.png)